118th Congress · HOUSE BILLBILL

H.R. 4242 — To direct the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, to issue guidance on considerations for conducting clinical trials for psychedelic assisted therapy.

“To direct the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, to issue guidance on considerations for conducting clinical trials for psychedelic assisted therapy.”

Health

Introduced Jun 21, 2023

Last action Jun 23, 2023

Pipeline · Bill → Law

Step 1

Introduced

Jun 21, 2023

Step 2

Referred

Jun 23, 2023

E&C

Step 3

Committee

Step 4

House floor

Step 5

Senate

Step 6

Resolve Changes

Step 7

Signed

SummaryCRS Summary

This bill requires the Food and Drug Administration (FDA) to issue guidance on considerations for conducting clinical trials for psychedelic assisted therapy, including how to request support from the FDA for related investigational use exemptions.

Provisions · 1 sectionsIntroduced in House

Timeline · 3 actions

Jun 23, 2023

Referred to the Subcommittee on Health.

Jun 21, 2023

Introduced in House

Jun 21, 2023

Referred to the House Committee on Energy and Commerce.